key: cord-1036251-ehqurwkb authors: Jääskeläinen, AE; Ahava, MJ; Jokela, P; Szirovicza, L; Pohjala, S; Vapalahti, O; Lappalainen, M; Hepojoki, J; Kurkela, S title: Evaluation of three rapid lateral flow antigen detection tests for the diagnosis of SARS-CoV-2 infection date: 2021-03-05 journal: J Clin Virol DOI: 10.1016/j.jcv.2021.104785 sha: 443b203d0535dfc6fa9e7c77a41b98e92630ecd3 doc_id: 1036251 cord_uid: ehqurwkb INTRODUCTION: The COVID-19 pandemic has led to high demand of diagnostic tools. Rapid antigen detection tests have been developed and many have received regulatory acceptance such as CE IVD or FDA markings. Their performance needs to be carefully assessed. MATERIALS AND METHODS: 158 positive and 40 negative retrospective samples collected in saline and analyzed by a laboratory-developed RT-PCR test were used to evaluate Sofia (Quidel), Standard Q (SD Biosensor), and Panbio™ (Abbott) rapid antigen detection tests (RADTs). A subset of the specimens was subjected to virus culture. RESULTS: The specificity of all RADTs was 100% and the sensitivity and percent agreement was 80% and 85% for Sofia, 81% and 85% for Standard Q, and 83% and 86% for Panbio™, respectively. All three RADTs evaluated in this study reached a more than 90% sensitivity for samples with a high viral load as estimated from the low Ct (Cycle threshold) values in the reference RT-PCR. Virus culture was successful in 80% of specimens with a Ct value <25. CONCLUSIONS: As expected, the RADTs were less sensitive than RT-PCR. However, they benefit from the speed and ease of testing, and lower price as compared to RT-PCR. Repeated testing in appropriate settings may improve the overall performance. The superior analytical sensitivity and specificity makes RT-PCR the primary diagnostic tool for the detection of SARS-CoV-2 in respiratory samples [1] [2] . Rapid antigen detection tests (RADTs) can be cheap and easy to use compared to RT-PCR. Contrary to PCR, antigen tests do not amplify the detected target, rendering them generally less sensitive [3] . The SARS-CoV-2 RADTs are relatively new in the market, without extensive evaluation. They appear to show variable performance: according to a systematic review published in August 2020, RADT sensitivity varied from 0% to 94% [4] . We evaluated three CE IVD marked SARS-CoV-2 RADTs: Sofia (Quidel), Standard Q COVID-19 Ag (SD Biosensor), and Panbio™ (Abbott). In each of these tests, the sample is suspended or diluted in a sample inactivation medium and transferred to a test device. If SARS-CoV-2 antigen is present above a threshold concentration, a line will appear in the test device within 15 minutes. For Panbio™ and Standard Q, the line is visible for a naked eye, and for Sofia, detection of the fluorescent signal is automated. The evaluation was performed at the diagnostic laboratory of Helsinki University Hospital and Helsinki and Uusimaa Hospital District, Finland. Research permit HUS/157/2020 (Helsinki University Hospital, Finland) was obtained from the local review board. We evaluated the performance of Quidel Sofia SARS FIA (Quidel, San Diego, CA), Standard Q COVID-19 Ag test (SD Biosensor, Republic of Korea), and Panbio™ (Abbott Diagnostic GmbH, Jena, Germany) according to each manufacturer's guidelines for samples in virus transport medium. All evaluated J o u r n a l P r e -p r o o f 5 tests are intended for fresh swab samples, so this is off-label use and leads to dilution of samples, see Table 1 . The samples were originally analyzed with a laboratory-developed RT-PCR test (LDT) based on the method by Corman and others [5] and modified by us [6] to detect the N gene target of SARS-CoV-2. A total of 198 nasopharyngeal swabs in 0.9% saline taken between April and November 2020 and stored in -20°C were available for the study. To investigate the test performance in an outpatient setting, another set of LDT positive samples from adults from outpatient clinics and drive-through testing sites was included by selecting samples systematically backwards from 18 November until 96 specimens were reached, i.e. November 1-18 2020. Samples from hospitals and occupational health services were excluded, as well as samples that had less than the required 750 µl for three RADTs left. Due to variable amount of test devices available, eighty-seven samples were analyzed by Sofia, 90 by Panbio™ and 96 by Standard Q. 59 specimens of the PCR positive subset used for analytical performance evaluation was subjected to virus isolation experiments in Vero E6 TMRPSS2 cells as described in [7] . Concordance of the results was examined in McNemars's test. Level of statistical significance was set at P<0.05. Cohen's kappa coefficient was computed to assess the agreement between the methods Table 2) . At the analytical evaluation of the tests we used 40 negative and 62 positive samples in LDT, that were chosen to include a wide range of Ct values. When Ct in RT-PCR was <25, sensitivity of all three RADTs was 100% and virus culture 80%. When Ct in RT-PCR was ≥30, the sensitivity was much lower ( Table 2) . Compared to RT-PCR, the sensitivity of RADTs is low: in the present study the sensitivity was only 12-38% in samples with Ct≥30 (Table 2) . However, the distribution of Ct values of RT-PCR positive samples in settings where antigen detection tests could primarily be used is unknown. We wanted to approach the real-life setting by testing all positive outpatient adult samples tested by LDT in our laboratory during 2.5 weeks in November 2020. The testing strategy in Finland in November 2020 assumed patients to have at least mild symptoms of SARS-CoV-2 infection. Thus, this panel is unlikely to include asymptomatic or presymptomatic patients. In November 2020 the sampling was available in average within 12 hours of seeking for testing. Although medical records of outpatients were not available, we assume the majority of this panel to consist of samples taken within a couple of days from symptom onset. 78% of samples had a Ct value <25, and 95% <30, in our LDT. This may justify using antigen tests as a diagnostic tool even when their sensitivity compared to nucleic acid testing is poor for samples with high Ct values. Careful consideration between the advantages (ease, speed, costs) and disadvantages (lower sensitivity) needs to be conducted in the selection of appropriate testing strategies [11] [12] . If RADTs are considered, laboratories need to perform independent clinical validations, as manufacturers' declaration of performance may not include satisfactory selection of clinical samples. WHO has stated SARS-CoV-2 a biohazard risk for laboratory personnel [13] , which needs to be accounted for in RADT testing. In addition, RATDs are not easily scalable for mass testing. This may lead to underestimation of the sensitivity of the antigen detection tests. All three RADTs, Sofia, Standard Q and Panbio™, were specific but less sensitive than RT-PCR. However, RADTs do have other advantages over PCR tests, such as shorter turnaround time and lower price. Together with the availability of testing outside central laboratories, these features enable repeated testing of individuals, which may increase the sensitivity of a testing regimen as a whole [14] . Indeed, simple and cheap RADTs with a satisfactory performance, such as the three tests evaluated in this study, make repeated testing a realistic diagnostic approach in settings in which RT-PCR is not readily or quickly available. ☑The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. on behalf of the RECOVER project and collaborating networks. International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic Comparison of seven commercial RT-PCR diagnostic kits for COVID-19 Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction. A systematic review and metaanalysis Van den Bruel A, Cochrane COVID-19 Diagnostic Test Accuracy Group: Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT Comparison of two commercial platforms and a laboratory developed test for detection of SARS-CoV-2 RNA A generic, scalable, and rapid TR-FRETbased assay for SARS-CoV-2 antigen detection Comparison of seven commercial SARS-CoV.2 rapid Pont-of-Care Antigen tests Spanish Panbio™ COVID-19 validation group: Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-Detection Test for the diagnosis of SARS-CoV-2 infection Evaluation of a SARS-CoV-2 rapid antigen test: potential to help reduce community spread? WHO: Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance WHO: Laboratory biosafety guidance related to coronavirus disease (COVID-19): interim guidance Rethinking Covid-19 test sensitivity -a strategy for containment We thank Marianne Ahola, Jenna Roivas and Laila Shakari for excellent technical assistance.J o u r n a l P r e -p r o o f